Coenzyme Q10 improves blood pressure and glycaemic control: A controlled trial in subjects with type 2 diabetes

European Journal of Clinical Nutrition

Volumn 56, Issue 11, 2002, Pages 1137-1142

  Hodgson, J M ^a   Watts, G F ^a   Playford, D A ^b   Burke, V ^a   Croft, K D ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b ROYAL PERTH HOSPITAL   (Australia)

Author keywords

Blood pressure; Coenzyme Q10; F2 isoprostanes; Glycaemic control; Oxidative stress

Indexed keywords

ANTILIPEMIC AGENT; ANTIOXIDANT; CALCIUM CHANNEL BLOCKING AGENT; COQ; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FENOFIBRATE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; ISOPROSTANE DERIVATIVE; UBIDECARENONE; DRUG DERIVATIVE; GLYCOSYLATED HEMOGLOBIN; UBIQUINONE;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; AUSTRALIA; BLOOD GLUCOSE MONITORING; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIET SUPPLEMENTATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DYSLIPIDEMIA; FEMALE; HEMOGLOBIN DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; BLOOD; BLOOD PRESSURE; DRUG EFFECT; GLUCOSE BLOOD LEVEL; HYPERLIPIDEMIA; METABOLISM; MIDDLE AGED;

ANTILIPEMIC AGENTS; ANTIOXIDANTS; BLOOD GLUCOSE; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; F2-ISOPROSTANES; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; OXIDATIVE STRESS; PROCETOFEN; UBIQUINONE;

EID: 0036827017     PISSN: 09543007     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ejcn.1601464     Document Type: Article

References (24)

1. Anderson RA, Evans ML, Ellis GR, Graham J, Morris K, Jackson SK, Lewis MJ, Rees A & Frenneaux MP (2001): The relationships between post-prandial lipaemia, endothelial function and oxidative stress in healthy individuals and patients with type 2 diabetes. Atherosclerosis 154, 475-483.
2. Bonnefont-Rousselot D, Bastard JP, Jaudon MC & Delattre J (2000): Consequences of the diabetic status on the oxidant/antioxidant balance. Diabetes Metabol. 26, 163-176.
3. Burke BE, Neuenschwander R & Olson RD (2002): Randomised double-blind, placebo-controlled trial of coenzyme Q10 in isolated systolic hypertension. Southern Med. J. 94, 1112-1117.
4. Ceriello A (2000): Oxidative stress and glycemic regulation. Metab. Clin. Exp. 49(Suppl 1). 27-29.
5. 10 on essential arterial hypertension. Curr. Ther. Res. 47, 841-845.
6. 10 administration on metabolic control in patients with type 2 diabetes mellitus. Biofactors 9, 315-318.
7. Grunfeld S, Hamilton CA, Mesaros S, McClain SW, Dominiczak AF, Bohr DF & Malinski T (1995): Role of superoxide in the depressed nitric oxide production by the endothelium of genetically hypertensive rats. Hypertension 26, 854-857.
8. Henriksen JE, Andersen CB, Hother-Nielsen O, Vaag A, Mortensen SA & Beck-Nielsen H (1999): Impact of ubiquinone (coenzyme Q(10)) treatment on glycaemic control, insulin requirement and well-being in patients with Type 1 diabetes mellitus. Diabetic Med. 16, 312-318.
9. Hodgson JM, Puddey IB, Croft KD, Mori TA, Rivera J & Beilin LJ (1999): Isoflavonoids do not inhibit in vivo lipid peroxidation in subjects with high-normal blood pressure. Atherosclerosis 145, 167-172.
10. 10, alpha-tocopherol, and free cholesterol levels in sera from diabetic patients. In: ed. K Folkers, G Littarru & T Yamagami. Biomedical and Clinical Aspects of Coenzyme Q, pp 151-158. Amsterdam: Elsevier Science.
11. Kitiyakara C & Wilcox CS (1998): Antioxidants for hypertension. Curr. Opin. Nephr. Hypertens. 7, 531-538.
12. Lang JK, Gohil K & Packer L (1986): Stimultaneous determination of tocopherols, ubiquinols and ubiquinones in blood, plasma, tissue homogenates, and sucellular fractions. Anal. Biochem. 157, 106-116.
13. Lawson JA, Rokach J & FitzGerald GA (1999): Isoprostanes: formation, analysis and use as indices of lipid peroxidation in vivo. J. Biol. Chem. 274, 24441-24444.
14. McCarty MF (1999): Can correction of sub-optimal coenzyme Q status improve beta-cell function in type II diabetics? Med. Hypoth. 52, 397-400.
15. Mori TA, Croft KD, Puddey IB & Beilin LJ (1999): An improved method for the measurement of urinary and plasma F2-isoprostanes using gas chromatography-mass spectrometry. Anal. Biochem. 268, 117-125.
16. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP, Giardino I & Brownlee M (2000): Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404, 787-790.
17. 10 in health and disease. Eur. J. Clin. Nutr. 53, 764-770.
18. Raitakari OT, McCredie RJ, Witting P, Griffiths KA, Letters J, Sullivan D, Stocker R & Celermajer DS (2000): Coenzyme Q improves LDL resistance to ex vivo oxidation but does not enhance endothelial function in hypercholesterolaemic young adults. Free Rad. Biol. Med. 28, 1100-1105.
19. Roberts LJ & Morrow JD (2000): Measurement of F(2)-isoprostanes as an index of oxidative stress in vivo. Free Rad. Biol. Med. 28, 505-513.
20. Singh RB, Niaz MA, Rastogi SS, Shukla PK & Thakur AS (1999): Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease. J. Hum. Hypertens. 13, 203-208.
21. Thomas SR, Witting PK & Stocker R (1999): A role for reduced coenzyme Q in atherosclerosis? Biofactors 9, 207-224.
22. 10 improves endothelial dysfunction of the brachial artery in type II diabetes mellitus. Diabetologia 45, 420-426.
23. West IC (2000): Radicals and oxidative stress in diabetes. Diabetic Med. 17, 171-180.
24. 10 on essential hypertension: a double blind controlled study. In: Biomedical and Clinical Aspects of Coenzyme Q, ed. K Folkers, G Littarru & T Yamagami, pp 337-343. Amsterdam: Elsevier Science.